The ASGR1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the ASGR1 gene has been disrupted within the A2780 human ovarian carcinoma cell line. This product provides a genetically heterogeneous loss-of-function model that bypasses single-cell cloning, thereby preserving population diversity and reducing clonal artifacts. It is specifically designed for applications that require stable, averaged ASGR1 knockout effects across a polyclonal pool.
A2780 is an epithelial ovarian cancer model established from an untreated patient with ovarian endometrioid adenocarcinoma. The cell line exhibits adherent growth, hormone sensitivity, and well-characterized genomic features, making it a versatile platform for cancer biology, drug sensitivity testing, and xenograft studies. Its malignant epithelial context is particularly relevant for exploring how glycoprotein clearance pathways and endocytic trafficking become dysregulated in cancer.
ASGR1 encodes the major subunit of the asialoglycoprotein receptor, a C-type lectin that mediates hepatic clearance of desialylated glycoproteins via clathrin-mediated endocytosis and lysosomal degradation. Transcriptional regulation is controlled by hepatocyte nuclear factor 4 alpha (HNF4A) and sterol regulatory element-binding protein 2 (SREBF2) in response to cholesterol. ASGR1 forms a heterodimer with ASGR2 and recruits clathrin and adaptor protein complex 2 (AP2) for receptor internalization. Downstream, ASGR1 activity influences lysosomal acid lipase, cathepsin D, and cholesterol efflux, thereby linking glycoprotein homeostasis to lipid metabolism.
Disruption of ASGR1 in A2780 cells creates a unique non-hepatic model that uncouples ASGR1 function from its native liver environment. Because ASGR1 is not endogenously expressed in this ovarian line, the knockout provides a clean background for forced expression, reconstitution, or complementation experiments aimed at dissecting structure?Cfunction relationships. This model also enables evaluation of ASGR1-targeted therapeutics, including antibody-drug conjugates or nanoparticle carriers, in a cancer-relevant setting without confounding endogenous receptor activity.
Key research applications include ligand uptake assays with asialoorosomucoid (ASOR) to quantify receptor-mediated endocytosis, immunofluorescence for tracking receptor internalization, and flow cytometry for measuring surface ASGR1 levels following ectopic expression. Lysosomal activity assays can assess degradative capacity, while transcriptomic profiling by RNA-seq reveals global changes in gene expression upon ASGR1 loss. These polyclonal knockout cells further support drug delivery studies targeting the asialoglycoprotein receptor. For additional technical details or to inquire about custom gene editing solutions, please contact Ascent Research.
